|
gptkbp:instanceOf
|
gptkb:drug
gptkb:granulocyte_colony-stimulating_factor
|
|
gptkbp:administeredAfter
|
chemotherapy
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2002
|
|
gptkbp:ATCCode
|
L03AA13
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:brand
|
gptkb:Neulasta
|
|
gptkbp:CASNumber
|
208265-92-3
|
|
gptkbp:category
|
immunostimulant
hematopoietic agent
|
|
gptkbp:contraindication
|
hypersensitivity to pegfilgrastim
|
|
gptkbp:developedBy
|
gptkb:Amgen
|
|
gptkbp:eliminationHalfLife
|
15-80 hours
|
|
gptkbp:form
|
pre-filled syringe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pegfilgrastim
|
|
gptkbp:indication
|
reduce infection risk in cancer patients
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
stimulates production of neutrophils
|
|
gptkbp:metabolism
|
renal
|
|
gptkbp:molecularWeight
|
39 kDa
|
|
gptkbp:monitoredParameter
|
white blood cell count
|
|
gptkbp:pegylated
|
yes
|
|
gptkbp:pegylationPurpose
|
prolong half-life
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:product
|
recombinant human G-CSF
|
|
gptkbp:relatedTo
|
gptkb:filgrastim
|
|
gptkbp:riskFactor
|
gptkb:acute_respiratory_distress_syndrome
allergic reactions
splenic rupture
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
bone pain
allergic reactions
splenic rupture
|
|
gptkbp:UNII
|
6XU8R8C8AP
|
|
gptkbp:usedFor
|
chemotherapy-induced neutropenia
prevention of neutropenia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Biocon_Biologics
|
|
gptkbp:bfsLayer
|
7
|